Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas

BACKGROUND Long-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment s...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Hirokazu Ogino, Jennie W. Taylor, Takahide Nejo, David Gibson, Payal B. Watchmaker, Kaori Okada, Atsuro Saijo, Meghan R. Tedesco, Anny Shai, Cynthia M. Wong, Jane E. Rabbitt, Michael R. Olin, Christopher L. Moertel, Yasuhiko Nishioka, Andres M. Salazar, Annette M. Molinaro, Joanna J. Phillips, Nicholas A. Butowski, Jennifer L. Clarke, Nancy Ann Oberheim Bush, Shawn L. Hervey-Jumper, Philip Theodosopoulos, Susan M. Chang, Mitchel S. Berger, Hideho Okada
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	American Society for Clinical Investigation 2022-02-01
Sarja:	The Journal of Clinical Investigation
Aiheet:	Oncology Vaccines
Linkit:	https://doi.org/10.1172/JCI151239
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!